Researchers Marta del Campo Milán and Gonzalo Herradón, from the NEUROFAN Group - Neuropharmacology of Addictions and Degenerative Disorders - along with twenty other experts from different countries, have published a study in Nature Aging magazine in which they analyse the cerebrospinal fluid proteome in patients at different stages of Alzheimer's disease and other types of dementia.
The results obtained reflect the multifactorial nature of Alzheimer's and identify specific biomarker panels. "With these personalised biomarker panels we can begin to define the development of the disease from a biological point of view, which can be useful for the detection of the disease in clinical practice or in clinical trials," explains lead author Marta del Campo.
This study is part of the Amsterdam Neuroscience research programme and was supported by both the Alzheimer Nederland and the Selfridges Group Foundations. Led by the VU Medical Center in Amsterdam, it involved 25 researchers from different European countries and the United States.
The investigation provides specific pathophysiological clues which outline the multifactorial nature of Alzheimer's disease throughout its development. In addition, they have identified and validated a set of cerebrospinal fluid biomarkers capable of differentiating Alzheimer's patients from the control group and other types of dementias which aren’t classified as Alzheimer’s. "The proteins found in these panels reflect the complex and multifactorial biology of Alzheimer's disease. It is important to mention that the technology used has allowed us to efficiently translate these customised panels into specific kits and validate them in an independent group of patients," states Del Campo.
More information:
Del Campo, M., Peeters, C.F.W., Johnson, E.C.B. et al. CSF proteome profiling across the Alzheimer’s disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panels. Nat Aging 2, 1040–1053 (2022). https://doi.org/10.1038/s43587-022-00300-1